Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

Hepatology

Volumn 37, Issue 2, 2003, Pages 443-451

  Schaefer, Martin ^a   Schmidt, Folkhard ^b   Folwaczny, Christian ^c   Lorenz, Reinhard ^c   Martin, Gaby ^b   Schindlbeck, Norbert ^c   Heldwein, Walter ^c   Soyka, Michael ^b   Grunze, Heinz ^b   Koenig, August ^c   Loeschke, Klaus ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA2A INTERFERON; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; METHADONE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; RIBAVIRIN; ZOLPIDEM; ZOPICLONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALOPECIA; ANAMNESIS; ANOREXIA; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RISK BENEFIT ANALYSIS; SELF INJECTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; VIREMIA; VIRUS LOAD; WITHDRAWAL SYNDROME;

EID: 0037308288     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50031     Document Type: Article

References (36)

1. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
2. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. HEPATOLOGY 1997;26:521-526.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
6. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. HEPATOLOGY 2001;34:188-193.
7. Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995;15:209-212.
8. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997;26:794-797.
9. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987;147:1577-1580.
10. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996:24:778-789.
11. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999;340:1370.
12. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999;156:1120.
13. Shad J, Person J, Brann O, Moon S, Pockros PJ, Nyberg L, Pianco S, et al. How often are referred chronic hepatitis C patients candidates for antiviral therapy [Abstract]. HEPATOLOGY 2000;32(Suppl):283A.
14. Taruschio G, Santarini F, Sica G, Dragoni C, Migliorini S, Andreone P, Cursaro C, et al. Psychiatric disorders in hepatitis C virus related chronic liver disease [Abstract]. Gastroenterology 1996;110:1342A.
15. Lynch P, Peters M, Quigley M, Sreenarasaimhiah J, Cladwell C. Impact of psychiatric disorders on treatment of patients with hepatitis C [Abstract]. Gastroenterology 1998;114(Suppl):1294A.
16. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001;96:157-164.
17. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders SCID I: clinical version 2.0. Rev. New York: Biometrics Research Department, New York State Psychiatric Institute, 1998.
19. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
20. Janssen HLA, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243.
21. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11242 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
22. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroent Hepatol 1995;7:165-168.
23. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354:131-132.
24. Cantell K, Pulkkinen E, Elosuo R, Suominen J. Effect of interferon on severe psychiatric diseases. Ann Clin Res 1980;12:131-132.
25. Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000;33:72-74.
26. Cabrera-Gomez JA, Gutierrez JR, Lopez O, Gutierrez B, Garcia K, Consuegra J, Cruz R, et al. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1994;7:27-37.
27. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993;88:760-761.
28. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001;345:375-376.
29. Schaefer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000;42(Suppl 1):43-45.
30. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361.
31. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;13:961-966.
32. Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. Semin Oncol 1998;25(Suppl I):54-63.
33. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-α therapy. Semin Oncol 1998;25(Suppl I):39-47.
34. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;534:211-215.
35. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001;534:215-216.
36. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-277.